Executive Summary – Alzheimer’s Association Small Company Consortium

SynAging SAS (www.synaging.com) is a European CRO supporting translational drug discovery, focused on improved models of proteopathic neurodegenerative diseases like Alzheimer’s disease, Parkinson’s disease, etc., overcoming past unclear preclinical results and high attrition. We are a world leader in the production of misfolded-protein-induced neurodegenerative diseases and do not work on transgenic models.

Meanwhile SynAging has extensive insights into proteopathic disease models induced by:
- Amyloid-β oligomers (and fibrils)
- α-synuclein oligomers and fibrils
- human tau oligomers (and fibrils)

SynAging offers in vitro ‘disease’ models for quick screening of therapeutic candidates in:
- Primary rodent neurons from cortex, hippocampus, or striatum, monitoring neurotoxicity
- Rodent astrocytes, monitoring activation of the innate immune system
- iPS cell derived human neuronal culture (incl. dopaminergic neurons)

SynAging offers in vivo ‘disease’ models in aggregate-inoculated (once) wt. mice for systemic, behavioral, and ex vivo biochemical investigations of therapeutic candidates. Validated behavioral readouts include:
- Y-Maze
- Morris Water Maze
- Novel Object Recognition
- Spatial Recognition Test

SynAging’s unique capabilities:
- high reproducibility over many oligomer preparations and years, in vitro and in vivo
- fast study performance: in vitro (one month), in mice (2-3 months)
- cost effective
- guaranteed performance of all controls
- scientific consulting with extensive expertise

SynAging is interested in service assignments on its existing models (fee for service) and collaborations to extend it’s current scope of indications induced by further misfolded proteins in temporary exclusive collaborations. We are also engaged in long term collaborations supporting drug discovery activities of our partners on a risk and revenue sharing basis.

Andreas Köpke, PhD, CBO
andreas.kopke@synaging.com
Tel.: +49 6136 957 3000
Fax: +49 6136 957 0384